115.25
price up icon0.31%   0.495
 
loading

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
Jul 30, 2025

Gilead and Arcus Advance Cancer Treatment Study with AB308 and Zimberelimab - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Are Wall Street Analysts Bullish On Gilead Sciences Stock? - Barchart.com

Jul 30, 2025
pulisher
Jul 30, 2025

Gilead files covid 19 remdesivir actions against Chinese military research institute - IAM Patent

Jul 30, 2025
pulisher
Jul 30, 2025

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

Jul 30, 2025
pulisher
Jul 29, 2025

NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360

Jul 29, 2025
pulisher
Jul 29, 2025

Gilead Sciences’ TAF Study in Children with Hepatitis B: An Update - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma

Jul 29, 2025
pulisher
Jul 29, 2025

Gilead Sciences’ Strategic Positioning and Growth Prospects in the HIV Prevention Market Justify Buy Rating - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Gilead price collects profitsForecast today29-07-2025 - Economies.com

Jul 29, 2025
pulisher
Jul 29, 2025

Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com

Jul 29, 2025
pulisher
Jul 29, 2025

Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Why Gilead Sciences Stock Slipped Today - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits

Jul 28, 2025
pulisher
Jul 28, 2025

Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily

Jul 28, 2025
pulisher
Jul 28, 2025

TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey

Jul 28, 2025
pulisher
Jul 28, 2025

Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey

Jul 28, 2025
pulisher
Jul 28, 2025

What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire

Jul 27, 2025
pulisher
Jul 27, 2025

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st

Jul 27, 2025
pulisher
Jul 27, 2025

Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu

Jul 27, 2025
pulisher
Jul 26, 2025

Gilead Sciences Stock Surges Amid Promising Trials - TipRanks

Jul 26, 2025
pulisher
Jul 26, 2025

10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences Stock Just Popped - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences (GILD) Receives Upgraded Rating from Needham | G - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Latest Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead upgraded to Buy at Needham on new HIV drug - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener

Jul 25, 2025
pulisher
Jul 25, 2025

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency For Twice-Yearly Lenacapavir For HIV Prevention - vih.org

Jul 25, 2025
pulisher
Jul 25, 2025

Is Gilead Sciences Inc. a good long term investmentMarket-leading profit generation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Why Gilead Sciences Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - beatles.ru

Jul 24, 2025
pulisher
Jul 24, 2025

Is Gilead Sciences Inc. stock a growth or value playTremendous gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Looking Back to the Future: Gilead’s Long-Standing Commitment To Help End the HIV Epidemic - CSRwire

Jul 24, 2025
pulisher
Jul 23, 2025

Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)

Jul 23, 2025
pulisher
Jul 23, 2025

AG Jackson announces major settlement with Gilead Sciences over kickbacks - WPDE

Jul 23, 2025
pulisher
Jul 23, 2025

Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView

Jul 23, 2025
drug_manufacturers_general PFE
$23.70
price down icon 0.35%
$300.52
price down icon 0.26%
drug_manufacturers_general NVO
$48.32
price down icon 3.41%
drug_manufacturers_general SNY
$45.61
price down icon 6.95%
drug_manufacturers_general MRK
$79.85
price down icon 2.32%
Kapitalisierung:     |  Volumen (24h):